A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

14.6K views

⸱

DOI:

10.3791/50409

⸱

July 6th, 2013

 ,  ,  , 

In This Article

Summary

Human Cytomegalovirus (HCMV) infection of neonates represents an important cause of mental retardation, yet the molecular events leading to virus-induced pathogenesis are still poorly understood. To investigate the dynamics of brain infection, we adapted whole-animal in vivo imaging to perform time-course analysis of neonates infected with a luciferase-recombinant virus.

Abstract

Human Cytomegalovirus (HCMV or HHV-5) is a life-threatening pathogen in immune-compromised individuals. Upon congenital or neonatal infection, the virus can infect and replicate in the developing brain, which may induce severe neurological damage, including deafness and mental retardation. Despite the potential severity of the symptoms, the therapeutic options are limited by the unavailability of a vaccine and the absence of a specific antiviral therapy. Furthermore, a precise description of the molecular events occurring during infection of the central nervous system (CNS) is still lacking since observations mostly derive from the autopsy of infected children. Several animal models, such as rhesus macaque CMV, have been developed and provided important insights into CMV pathogenesis in the CNS. However, despite its evolutionary proximity with humans, this model was limited by the intracranial inoculation procedure used to infect the animals and consistently induce CNS infection. Furthermore, ethical considerations have promoted the development of alternative models, among which neonatal infection of newborn mice with mouse cytomegalovirus (MCMV) has recently led to significant advances. For instance, it was reported that intraperitoneal injection of MCMV to Balb/c neonates leads to infection of neurons and glial cells in specific areas of the brain. These findings suggested that experimental inoculation of mice might recapitulate the deficits induced by HCMV infection in children. Nevertheless, a dynamic analysis of MCMV infection of neonates is difficult to perform because classical methodology requires the sacrifice of a significant number of animals at different time points to analyze the viral burden and/or immune-related parameters. To circumvent this bottleneck and to enable future investigations of rare mutant animals, we applied in vivo imaging technology to perform a time-course analysis of the viral dissemination in the brain upon peripheral injection of a recombinant MCMV expressing luciferase to C57Bl/6 neonates.

Introduction

Human Cytomegalovirus (HCMV/HHV-5) is a member of the β-herpesvirus family. HCMV is a highly prevalent, opportunistic pathogen which is usually acquired during early life as an asymptomatic infection 1. Like all herpesviruses, HCMV persists throughout the entire life of the host whose immune system tightly controls viral replication. Episodes of viral reactivation mostly occur in immunocompromised individuals such as transplant patients receiving drugs to prevent graft rejection 2. In adults, HCMV has also been linked to glioblastomas 3. In addition, HCMV is a prominent pathogen for newborns with immature immunity 4-6....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Preparation of Viral Suspension

  1. Obtain the Smith strain of MCMV expressing Luciferase (MCMV-Luc 15) from Ulrich Koszninowski's laboratory. In this recombinant, the Luciferase gene is inserted in the ie2 locus of the MCMV genome.
  2. To amplify MCMV-Luc, infect a murine bone marrow stromal cell line (M2-10B4, ATCC #CRL-1972) with MCMV at different multiplicity of infection (MOI, 0.001 to 1) 16. For this, add virus to cultured cells in serum free medium at 37 °C. After one hour, remove the supernatant and replace it with DMEM supplemented with 10% fetal calf serum (FCS). Five days later, harvest the culture medium ....

Access restricted. Please log in or start a trial to view this content.

Results

A representative experiment is illustrated in Figure 1. Upon intraperitoneal injection of 50 PFUs of MCMV-Luc (Panel A shows a similar injection performed with Methylene blue to visualize the subcutaneous route of the needle), neonates were anesthetized and received simultaneously 0.3 mg of the luciferase substrate (Luciferin, Caliper). Fifteen minutes later, animals were placed ventral side up in the acquisition chamber of the IVIS 50 (In Vivo Imaging System, Caliper) and the light emitted by the whole .......

Access restricted. Please log in or start a trial to view this content.

Discussion

Using in vivo imaging technology to monitor MCMV-Luc dissemination in mice neonates, we were able to observe viral spread to the brain of mutant animals, as opposed to wild-type. Further dissection of the animal and ex vivo imaging of the brain confirmed the presence of luminescent virus in the central nervous system. In addition, we also performed immunohistochemistry (not shown) on brain thin sections with an antibody specific for MCMV E1 early protein and observed that indeed, MCMV is present in the .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare no competing financial interest.

Ethics statement

Animals were maintained under pathogen-free conditions in the animal care facility of the Institut d'Immunologie et d'Hématologie. Handling of mice and experimental procedures were conducted in accordance with the French Law for the Protection of Laboratory Animals. The procedure was approved by the service véterinaire de la Préfecture du Bas-Rhin (France) under the authorization number A-67-345.

Acknowledgements

We thank Lee Tuddenham (IBMC, Strasbourg) for amplifying and titrating MCMV-Luc and Thomas Baumert (INSERM U748, Strasbourg) for permission to use the animal facility of the Institute of Virology. Financial support from INSERM, Université de Strasbourg and Agence Nationale de la Recherche (ANR-08-MIEN-005-01) is acknowledged. The initial participation of Sonia Beroud and Laetitia Lelieur during their Master project is also acknowledged.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Reagent/Material
DMEMFisher ScientificW3523A
Methylen blueSigma Aldrich319112
Insulin needlesVWR613-4897
KetamineCentraVetKet 201
Xylazine/VetranalSigma Aldrich46995
DPBSDUTSCHERP0436500
LuciferinCaliper760504
gentamycinSigma AldrichG1272
penicillin/streptomycinGibco15070
carboxymethylcelluloseSigma AldrichC4888
formaldehydeSigma AldrichF8775
crystal violetSigma AldrichC3886
Equipment
IVIS 50Caliper/Perkin Elmer

References

  1. Loewendorf, A., Benedict, C. A. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J. Intern. Med. 267, 483-501 (2010).
  2. Lischka, P., Zimmermann, H. Antiviral strategies to combat cy....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Neonatal InfectionLuciferase ExpressionPeritoneal InjectionViral DisseminationCentral Nervous SystemBioluminescence ImagingTime Course AnalysisAnimal Model